Clinical Trial

The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.

Recruiting
View on ClinicalTrials.gov →
Summary
Blood contains red blood cells, white blood cells, and platelets, as well as a fluid portion termed plasma. We primarily study blood platelets, but sometimes we also analyze the blood of patients with red blood cell disorders (such as sickle cell disease), white blood cell disorders, and disorders of the blood clotting factors found in plasma. Blood platelets are small cell fragments that help people stop bleeding after blood vessels are damaged. Some individuals have abnormalities in their blood platelets that result in them not functioning properly. One such disorder is Glanzmann thrombasthenia. Most such patients have a bleeding disorder characterized by nosebleeds, gum bleeding, easy bruising (black and blue marks), heavy menstrual periods in women, and excessive bleeding after surgery or trauma. Our laboratory performs advanced tests of platelet function and platelet biochemistry. If we find evidence that a genetic disorder may be responsible, we analyze the genetic material (DNA and RNA) from the volunteer, and when possible, close family members to identify the precise defect.
Protocol Amendment History 32 amendments
This ClinicalTrials.gov record has been amended 32 times since 2005-09-28; most recent amendment 2025-10-15.
Status change: Active, Not Recruiting → Recruiting 2020-06-03
Status change: Recruiting → Active, Not Recruiting 2020-04-13
Trial Details
NCT Number NCT00230165
Lead Sponsor Rockefeller University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Glanzmann Thrombasthenia
Enrollment 60 participants
Start Date 2005-09
Primary Completion 2030-06 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2025-10-20